中国肛肠病杂志2025，Vol.45Issue(6)：18-20,3.
维得利珠单抗联合益生菌对中重度溃疡性结肠炎患者炎性因子及肠黏膜屏障功能的影响
Effect of Vedolizumab Combined with Probiotics on Inflammatory Factors and Intestinal Mucosal Barrier Function in Patients with Moderate to Severe Ulcerative Colitis
刘春侠 1程文博 1关永天 1巩跃生1
作者信息
- 1. 郑州市大肠肛门病医院/河南中医药大学附属郑州市大肠肛门病医院(河南郑州 450000)
- 折叠
摘要
Abstract
Objective To investigate the effect of vedolizumab combined with probiotics on inflammatory factors and mucosal barrier function in patients with moderate to severe ulcerative colitis(UC).Methods A total of 82 patients with moderate to severe UC admitted to our hospital from March 2022 to March 2024 were selected and randomly divided into an observation group and a control group,with 41 cases in each group.The control group was treated with vedolizumab,while the observation group was given vedol-izumab combined with probiotics.The disease severity scores,levels of inflammatory factors,mucosal bar-rier function indexes and safety were compared between the two groups.Results There were no signifi-cant differences in the observational indexes between the two groups before treatment(P＞0.05).After treatment,the disease severity scores,levels of diamine oxidase and D-lactic acid,C-reactive protein,tumor necrosis factor-α and interleukin-6 in both groups were significantly decreased,which were lower in the ob-servation group than in the control group(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion The combined treatment of vedol-izumab and probiotics in patients with UC has a better effect,which is beneficial to improving symptoms,reducing the inflammatory response,repairing the mucosal barrier function,and does not significantly in-crease the incidence of adverse reactions.关键词
溃疡性结肠炎/维得利珠单抗/益生菌/炎性因子/肠黏膜屏障功能Key words
Ulcerative colitis/Vedolizumab/Probiotics/Inflammatory factors/Intestinal mucosal barrier function引用本文复制引用
刘春侠,程文博,关永天,巩跃生..维得利珠单抗联合益生菌对中重度溃疡性结肠炎患者炎性因子及肠黏膜屏障功能的影响[J].中国肛肠病杂志,2025,45(6):18-20,3.
